Skip to main content
. 2018 Feb 22;9(3):315. doi: 10.1038/s41419-018-0354-y

Fig. 2. JQ1 and Bortezomib exhibit synergistic cytotoxicity in BETi-resistant cells.

Fig. 2

a Representative phase contrast microscope images of LoVo and HCT116 cells treated with JQ1 (1 μM), Bortezomib (5 nM), or JQ1+Bortezomib for 72 h. b LoVo and HCT116 cells were treated with JQ1 (1 μM), Bortezomib (5 nM), or JQ1+Bortezomib for 48 h. Cell apoptosis was analyzed by Annexin V/PI staining. c Western blot of cleaved PARP1 in the HCT116 and LoVo cells treated with indicated compounds. d LoVo and HCT116 cells were treated with JQ1 (1 μM), Bortezomib (5 nM), or JQ1+Bortezomib for 48 h. Cell cycles were analyzed by PI staining. e Immunohistochemical staining of Ki67, cleaved PARP in xenograft tumor sections of HCT116 cells. Bar, 100 μm